Thomas H Rushmore

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes
    Thomas H Rushmore
    Department of Drug Metabolism, Merck Research Laboratory, West Point, PA, USA
    Curr Drug Metab 3:481-90. 2002
  2. ncbi request reprint Selective inhibition of dog hepatic CYP2B11 and CYP3A12
    Ping Lu
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    J Pharmacol Exp Ther 313:518-28. 2005
  3. pmc Mapping the genetic architecture of gene expression in human liver
    Eric E Schadt
    Rosetta Inpharmatics, Seattle, Washington, United States of America
    PLoS Biol 6:e107. 2008
  4. ncbi request reprint Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activity
    Christopher R Gibson
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    Drug Metab Dispos 33:1044-51. 2005
  5. ncbi request reprint Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression
    Dylan P Hartley
    Dept of Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065, USA
    Mol Pharmacol 65:1159-71. 2004
  6. ncbi request reprint Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol
    Michael L Schrag
    Drug Metabolism Department, Merck Research Laboratories, West Point, Pennsylvania, USA
    Drug Metab Dispos 32:1299-303. 2004
  7. ncbi request reprint Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450
    Magang Shou
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    Drug Metab Dispos 31:1161-9. 2003
  8. ncbi request reprint Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers
    Susie Xiujiang Li
    Merck Research Laboratories, PO Box 4, West Point, Pennsylvania 19486, USA
    J Clin Pharmacol 46:792-801. 2006
  9. ncbi request reprint Inhibition kinetics of monoclonal antibodies against cytochromes P450
    Qin Mei
    Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Drug Metab Dispos 30:701-8. 2002
  10. ncbi request reprint Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences
    A David Rodrigues
    Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    Curr Drug Metab 3:289-309. 2002

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes
    Thomas H Rushmore
    Department of Drug Metabolism, Merck Research Laboratory, West Point, PA, USA
    Curr Drug Metab 3:481-90. 2002
    ....
  2. ncbi request reprint Selective inhibition of dog hepatic CYP2B11 and CYP3A12
    Ping Lu
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    J Pharmacol Exp Ther 313:518-28. 2005
    ..Therefore, it is concluded that one can attempt to conduct P450 reaction phenotype studies with DLM using MBA and KET as selective inhibitors of CYP2B11 and CYP3A12, respectively...
  3. pmc Mapping the genetic architecture of gene expression in human liver
    Eric E Schadt
    Rosetta Inpharmatics, Seattle, Washington, United States of America
    PLoS Biol 6:e107. 2008
    ..We also identify SORT1 and CELSR2 as candidate susceptibility genes for a locus recently associated with coronary artery disease and plasma low-density lipoprotein cholesterol levels in the process...
  4. ncbi request reprint Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activity
    Christopher R Gibson
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    Drug Metab Dispos 33:1044-51. 2005
    ..It is concluded that the autoinduction observed after multiple treatments with compound I occurs since compound I is both an inducer and a substrate for dog CYP1A...
  5. ncbi request reprint Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression
    Dylan P Hartley
    Dept of Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065, USA
    Mol Pharmacol 65:1159-71. 2004
    ..Overall, these results suggest that ligand-mediated activation of PXR and induction of hepatic, rather than small intestinal, drug metabolism genes would contribute to the increased metabolism of orally administered pharmaceuticals...
  6. ncbi request reprint Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol
    Michael L Schrag
    Drug Metabolism Department, Merck Research Laboratories, West Point, Pennsylvania, USA
    Drug Metab Dispos 32:1299-303. 2004
    ..Collectively, these data are consistent with SULT1E1 as the primary sulfotransferase involved in EE sulfation at clinically relevant concentrations (<10 nM)...
  7. ncbi request reprint Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450
    Magang Shou
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    Drug Metab Dispos 31:1161-9. 2003
    ....
  8. ncbi request reprint Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers
    Susie Xiujiang Li
    Merck Research Laboratories, PO Box 4, West Point, Pennsylvania 19486, USA
    J Clin Pharmacol 46:792-801. 2006
    ..01-1.18], Cmax, 1.08 [90% CI, 0.94-1.24]). Aprepitant did not affect the pharmacokinetics of hydrodolasetron, regardless of CYP2D6 metabolizer type, and was generally well tolerated when coadministered with dolasetron in volunteers...
  9. ncbi request reprint Inhibition kinetics of monoclonal antibodies against cytochromes P450
    Qin Mei
    Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Drug Metab Dispos 30:701-8. 2002
    ....
  10. ncbi request reprint Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences
    A David Rodrigues
    Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    Curr Drug Metab 3:289-309. 2002
    ..In the past, such paradigms have not been as influential and there are numerous examples of marketed drugs that are metabolized by polymorphic CYPs...
  11. ncbi request reprint Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse
    Catherine L Booth-Genthe
    Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA
    J Pharmacol Toxicol Methods 54:78-89. 2006
    ..Here, we describe the development and characterization of LLC-PK1 cells expressing rat Abcb1...
  12. ncbi request reprint Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450
    Kristy K Michael Miller
    Department of Biochemistry and Molecular Biology, The University of Louisville School of Medicine, Louisville, Kentucky 40292, USA
    Drug Metab Dispos 32:305-13. 2004
    ..These results indicate that the stereo- and regioselectivity of hydroxylation by different P450s account for the diverse DHEA metabolites formed among various species...